A continued and robust federal investment in research funding will improve outcomes for pancreatic cancer patients diagnosed today and in the future.

**YOU CAN’T IGNORE THESE FACTS**

- Pancreatic cancer is one of the deadliest major cancers and has the lowest five-year survival rate at just **10%**.¹
- It is the **3rd leading cause of cancer-related deaths** and is projected to be the 2nd cause of cancer-related deaths by 2030 in the U.S.¹,²
- There is **no early detection method**.
- There are **few effective treatment options**.

**WHY NIH & NCI?**

National Institutes of Health (NIH) and National Cancer Institute (NCI) funding supports the foundational science necessary to accelerate early detection strategies and more effective treatments.

NIH funding is critical to the nation’s economy and job creation, contributing to:

- More than **$91 billion** in economic activity³
- 536,900 jobs³

More NCI funding correlates with increased survival:

- **$182.1 million** 2018
- **$17.3 million** 1999
- **10%** 2021
- **4%** 1999

**THE PANCREATIC CANCER ACTION NETWORK URGES THE 117TH CONGRESS TO HELP PATIENTS LIVE LONGER AND BETTER LIVES BY**

Funding **$46.1 billion** for the NIH in FY 2022, including **$7.6 billion** for the NCI.

---

³ NIH’s Role in Sustaining the U.S. Economy 2021 Update, United for Medical Research (accessed: March 2021).